SpringWorks Therapeutics (SWTX) has announced that the U.S. Food and Drug Administration has approved Gomekli, a small molecule MEK inhibitor, ...

Tuesday, the agency signed off on SpringWorks’ Gomekli (mirdametinib) as a treatment for the rare genetic disorder ...

In a regulatory filing, SpringWorks Therapeutics (SWTX) disclosed that its CEO Saqim Islam sold 48K shares of common stock on February 10th in ...

The FDA on Tuesday signed off on SpringWorks Therapeutics’ mirdametinib—now to carry the brand name Gomekli—for the treatment ...

Approval makes Gomekli the first treatment to be approved for both adults and pediatric patients for neurofibromatosis type 1 ...

Stamford, Connecticut-based SpringWorks' Gomekli (mirdametinib) has become the first medicine approved for both adults and ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.BoQAct6R.js ...

Edris Badreddin, Chief Operating Officer of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), sold 30,000 shares of the company's ...

The FDA's green light for GOMEKLI is a significant achievement for SpringWorks, especially as it comes with a rare pediatric disease priority review voucher, which could be valued at around $100 ...

Julie Hambleton, a director at SpringWorks Therapeutics Inc . (NASDAQ:SWTX), recently sold shares valued at approximately $730,206, according to a recent SEC filing. The transaction involved the sale ...

The US Food and Drug Administration approved Gomekli (mirdametinib), from SpringWorks Therapeutics, a kinase inhibitor, for adult and pediatric patients two years of age and older with ...

Snagging its second U.S. FDA approval since being spun out of Pfizer Inc. in 2017, Springworks Therapeutics Inc. is aiming to position Gomekli (mirdametinib), cleared for neurofibromatosis type ...